Latest Articles
newsGP - Triptorelin PBS expansion offers alternative treatment option - Royal Australian College of General Practitioners (RACGP)
newsGP - Triptorelin PBS expansion offers alternative treatment option Royal Australian College of General Practitioners (RACGP)
Published: Sept. 17, 2026, 6:56 a.m.
newsGP - Triptorelin PBS expansion offers alternative treatment option - racgp.org.au
newsGP - Triptorelin PBS expansion offers alternative treatment option racgp.org.au
Published: Sept. 17, 2026, 6:56 a.m.
newsGP - PBAC backs triptorelin PBS expansion - Royal Australian College of General Practitioners (RACGP)
newsGP - PBAC backs triptorelin PBS expansion Royal Australian College of General Practitioners (RACGP)
Published: Aug. 17, 2026, 6:59 a.m.
newsGP - PBAC considers PBS access to triptorelin for women’s health - Royal Australian College of General Practitioners (RACGP)
newsGP - PBAC considers PBS access to triptorelin for women’s health Royal Australian College of General Practitioners (RACGP)
Published: July 28, 2026, 6:57 a.m.
Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report.
Advanced maternal age (AMA) is a major challenge in reproductive medicine, compounded by coexisting conditions such as adenomyosis and endometriosis, which impair oocyte competence and endometrial receptivity. Prolonged gonadotropin-releasing hormone …
Published: May 19, 2026, midnight
[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial].
Objective: To evaluate the efficacy and safety of triptorelin acetate microspheres for injection compared with triptorelin acetate for injection in the treatment of endometriosis. Methods: A total of 392 patients …
Published: Jan. 31, 2026, midnight
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data - Nature
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data Nature
Published: Sept. 1, 2025, 5:12 a.m.
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …
Published: Sept. 1, 2025, midnight
The Role of GnRH Agonist Therapy and Hysterosalpingography (HSG) in Diagnosing and Treating Tubal Factor Infertility.
The paper describes the treatment of a 27-year-old woman with a history of infertility, heavy menstrual periods, and severe endometriosis with bilateral hydrosalpinx. The patient received hormonal treatment with triptorelin …
Published: Dec. 5, 2024, midnight
Link copied to clipboard!